American Century Companies Inc. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 9.5% during ...

Xponance Inc. lifted its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 25.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,148 shares of ...

Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing therapies in neuroscience, immunology, and oncology.,Research pipeline includes ...

NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... Wedbush analyst Laura Chico maintained a Buy rating on Biohaven ...

In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.47 per share. By comparison ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks with heavy insider buying in 2025. Insider trading is often seen as an important ...

Biohaven Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological and neuropsychiatric diseases. The company’s portfolio ...